Pancragen

Pancragen (KEDW, Lys-Glu-Asp-Trp-NH2) is a synthetic tetrapeptide bioregulator developed by Professor Vladimir Khavinson's group at the St. Petersburg Institute of Bioregulation and Gerontology. It is derived from bovine pancreatic tissue and proposed to restore age-related decline in pancreatic islet cell function. Among the Khavinson-class bioregulator tetrapeptides, Pancragen has the strongest human evidence: a small uncontrolled clinical study published in 2011 reported improvements in glucose tolerance and insulin resistance in elderly type 2 diabetics.

Note on sequence: some vendor sources incorrectly list Pancragen as a hexapeptide (Lys-Glu-Asp-Pro-Glu-Pro). Published peer-reviewed literature (PMIDs 18642713, 22448364) consistently gives the tetrapeptide sequence KEDW (Lys-Glu-Asp-Trp-NH2).

Pancragen belongs to the Russian peptide bioregulator class theorized to act through epigenetic and transcriptional mechanisms rather than classical receptor-ligand pharmacology. The short tetrapeptide sequence is proposed to penetrate cell and nuclear membranes and interact with regulatory DNA sequences in pancreatic islet cells, modulating gene expression programs that govern insulin synthesis, beta-cell survival, and glucose sensing.

At the physiological level, animal studies show Pancragen normalizes endothelial adhesion and permeability in diabetic microvasculature (IM route) and reduces hyperglycemia (oral route) in streptozotocin models. The human clinical observation links Pancragen's putative mechanism to melatonin: elderly type 2 diabetics have approximately 70% lower nocturnal melatonin levels than healthy controls, and melatonin is proposed to regulate islet cell function via MT1/MT2 receptors. Pancragen may restore downstream metabolic gene programs that melatonin deficiency disrupts.

This mechanistic model remains largely theoretical and lacks the receptor-binding pharmacology characterization available for classical peptide drugs.